Meeting
2022 ASCO Annual Meeting
Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy.
Authors
Jeffrey L. Wong
Memorial Sloan Kettering Cancer Center, New York, NY
Jeffrey L. Wong , David Knorr , Karissa Whiting , Venkatraman E. Seshan , Eugene J. Pietzak , Timothy F. Donahue , Eugene K. Cha , Alvin C. Goh , Robert Smith , Guido Dalbagni , Marlena McGill , Christian Hernandez , Melissa McCarter , Jonathan E. Rosenberg , Bernard H. Bochner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT05126472
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4616)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4616
Abstract #
TPS4616
Poster Bd #
98a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).
First Author: Ashish M. Kamat
Poster
2023 ASCO Annual Meeting
A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.
First Author: Hizra Farrukh
Poster
2023 ASCO Genitourinary Cancers Symposium
Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.
First Author: Ashish M. Kamat
Poster
2023 ASCO Annual Meeting
Phase 1b/2 dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer.
First Author: Wei Sun